Nootropic Peptides: A Research Overview for 2025
A comprehensive research overview of the leading nootropic peptides — Semax, Selank, BPC-157, Epithalon, and mitochondrial peptides — and what the current science shows.
Disclaimer: This article is for research and educational purposes only. It does not constitute medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Introduction: The Nootropic Peptide Landscape in 2025
The field of nootropic peptide research has undergone a significant maturation over the past decade. What was once a niche area of Russian neuropharmacology — largely inaccessible to Western researchers due to language barriers and regulatory differences — has become a growing focus of international preclinical investigation. The increasing availability of high-purity research compounds, improvements in peptide synthesis, and growing interest in personalised cognitive health have accelerated the field considerably.
This overview provides a structured summary of the major nootropic peptide categories as of 2025, examining the mechanisms, research base, and relative positioning of each. For Australian researchers and clinicians seeking a detailed guide to the regulatory landscape and research access, the nootropic peptides Australia overview provides essential context.
ACTH Analogues: Semax
The adrenocorticotropic hormone (ACTH) analogue class is represented primarily by Semax — a heptapeptide derived from the ACTH 4–10 fragment that retains the cognitive and neuroprotective properties of the parent hormone without hormonal activity. Semax is the most extensively researched nootropic peptide in the Russian clinical literature, with studies spanning stroke rehabilitation, cognitive impairment, attention deficit conditions, and optic nerve disease.
The core mechanisms of Semax — BDNF and NGF upregulation, melanocortin receptor modulation, and dopaminergic/serotonergic tone enhancement — give it a broad cognitive profile that includes improvements in memory consolidation, attention, and executive function. Its neuroprotective effects under ischaemic conditions and its intranasal delivery format have made it a staple compound in peptide research protocols.
A detailed examination of Semax's mechanisms and clinical research base is available in our dedicated article on Semax and cognitive performance (PMID: 12785797).
Anxiolytic Peptides: Selank
Selank, a tuftsin analogue developed at the Institute of Molecular Genetics in Moscow, represents the most researched peptidergic anxiolytic in the nootropic category. Its mechanism — GABAergic modulation without receptor downregulation, IL-6 normalisation, and BDNF upregulation — distinguishes it from classical anxiolytics and positions it as a research tool for studying the pharmacological separability of anxiolytic and sedative effects.
The 2024–2025 research trend in Selank studies has focused on its immunomodulatory properties in the context of neuroinflammation, following growing recognition of the gut-brain-immune axis as a driver of anxiety and mood disorders. Early findings suggest that Selank's IL-6 regulatory activity may have downstream effects on hippocampal neurogenesis and stress-induced cognitive impairment.
For a detailed mechanistic comparison, see our article on Selank and anxiety. The differences and complementarities between Semax and Selank — two of the most commonly researched peptides in this space — are discussed in the Semax vs Selank comparison. RetaLABS maintains a peptide research catalogue covering most of the compounds discussed in this article.
Gut-Brain Peptides: BPC-157
BPC-157 occupies a unique position in the nootropic peptide landscape as a compound with both peripheral (gastrointestinal, musculoskeletal) and central (neurological) research applications. Its derivation from human gastric juice gives it a distinctive origin, and its broad biological activity — spanning dopaminergic and serotonergic modulation, VEGF upregulation, and GABAergic effects — reflects its role as a multi-system regulatory peptide.
The 2024–2025 period has seen growing research interest in BPC-157's gut-brain axis effects, particularly in the context of the emerging understanding that enteric nervous system signalling influences central neurological health. BPC-157's demonstrated effects on both gut barrier integrity and central neurotransmitter systems make it a research tool for studying these bidirectional pathways.
BPC-157 does not have an approved form for human use in most Western jurisdictions and remains strictly a research compound outside of the countries where it has received limited clinical recognition.
Telomere Peptides: Epithalon
Epithalon (also written Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural peptide Epithalamin, extracted from the pineal gland. Developed by Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology, Epithalon is notable for being one of the first compounds demonstrated to activate telomerase — the enzyme responsible for extending telomere length at chromosome ends — in human somatic cells.
The telomere-longevity connection makes Epithalon one of the most theoretically compelling anti-ageing research compounds available. In addition to telomerase activation, Epithalon normalises pineal gland melatonin production, exerts antioxidant effects in neural tissue, and has demonstrated lifespan extension in multiple animal models. The neurological relevance stems from evidence that telomere shortening in neuronal progenitor cells contributes to the age-related decline in neurogenesis and cognitive reserve.
Mitochondrial Peptides: MOTS-c and SS-31
The mitochondrial peptide category — encompassing MOTS-c and SS-31 among others — represents the most recent major development in nootropic peptide research. MOTS-c, encoded within mitochondrial DNA, functions as an AMPK activator and nuclear stress response coordinator. Its age-related decline and demonstrated effects on metabolic resilience position it as a high-priority target for cognitive longevity research.
SS-31 (Elamipretide) operates through a complementary mechanism — direct cardiolipin binding and inner mitochondrial membrane stabilisation — that preserves ETC efficiency, reduces ROS production, and restores ATP generation in aged and damaged neurons. Together, MOTS-c and SS-31 represent mechanistically distinct but functionally complementary approaches to maintaining neuronal mitochondrial health.
The emergence of mitochondrial peptides as a research category reflects a broader shift in the field toward understanding neurological ageing at the level of cellular energetics rather than purely through neurotransmitter systems.
2024–2025 Research Trends
Several themes characterise the current frontier of nootropic peptide research. First, there is increasing focus on combination protocols — using peptides with complementary mechanisms to achieve synergistic effects on cognitive performance and neuroprotection. Second, the gut-brain axis is emerging as a key mediator of peptide effects, with implications for how peptides are dosed and delivered. Third, the translation of preclinical mitochondrial peptide findings into human research is accelerating, driven by SS-31's progression through clinical trials for cardiac and renal indications.
Finally, the application of peptide research to the specific context of cognitive longevity — rather than acute cognitive enhancement — is gaining momentum as the ageing population creates demand for evidence-based interventions targeting cognitive healthspan.
Summary
The nootropic peptide field in 2025 encompasses a diverse array of compounds with mechanistically distinct but often complementary profiles. From ACTH analogues and tuftsin derivatives to gut-origin peptides, telomere regulators, and mitochondrial signalling molecules, the research landscape offers unprecedented tools for investigating the biology of cognitive performance and neurological health. The convergence of improved synthesis methods, growing research access, and deepening mechanistic understanding sets the stage for significant translational advances in the years ahead.